BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
NCT ID: NCT04018248
Last Updated: 2025-09-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
26 participants
INTERVENTIONAL
2020-04-21
2023-09-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The Phase Ia (dose escalation) part of the study is designed to determine the safety, tolerability, and maximum tolerated dose (MTD)/recommended dose for expansion (RP2D) of BR101801 in subjects with relapsed/refractory B cell lymphoma, chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), and peripheral T cell lymphoma (PTCL).
The Phase Ib (dose expansion) part of the study is designed to assess tumor response and safety in specific advanced relapsed/refractory Peripheral T-cell lymphoma(PTCL) at a dose of BR101801 identified in Phase Ia. Once the RP2D has been determined in Phase Ia (dose escalation), Phase Ib (dose expansion) will commence.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase I Study of BR108 in Hematological Malignancies
NCT06018506
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
NCT04072458
A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies
NCT00719836
Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies
NCT03588598
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
NCT01435720
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary Objectives
* To assess the safety and tolerability of BR101801 in patients with relapsed/refractory B-cell lymphoma, CLL/SLL, and PTCL.
* To assess DLT and to determine the MTD and/or the RDE dose for BR101801 when administered orally on a daily schedule in 4-week cycles until disease progression.
SecondaryObjectives
* To characterize the plasma and urine PK of BR101801.
* To assess the preliminary antitumor activity of BR101801.
2. Phase Ib (Dose Expansion)
Primary Objectives
• To assess the safety and tolerability of BR101801 at the RP2D dose in subjects with relapsed/refractory Peripheral T-cell lymphoma (PTCL).
SecondaryObjectives
* To assess clinical activity of BR101801 when administered orally on a daily schedule in 4-week cycles until disease progression.
* To assess the plasma PK of BR101801.
OUTLINE: This is a Phase I, multi-center, open-label, FIH study. The safety monitoring committee(SMC) will be responsible for safety oversight.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (BR101801): Phase Ia (dose escalation)
Patients will receive BR101801 capsules orally, QD in 28-day cycles. The regimen may be changed to BID dosing based on emerging data.
BR101801 (Phase Ia)
Phase Ia (dose escalation):25 mg capsules and 100 mg capsules Planned doses are 50, 100, 200, 325, and 450 mg.
Treatment (BR101801):Phase Ib (dose expansion)
• Subjects with PTCL NOS, PTCL AITL, Nodal PTCL with TFH and PTCL FTCL
BR101801 (Phase Ib)
Phase Ib (dose expansion):25 and 100 mg capsules Doses administered will be determined from Phase Ia data.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BR101801 (Phase Ia)
Phase Ia (dose escalation):25 mg capsules and 100 mg capsules Planned doses are 50, 100, 200, 325, and 450 mg.
BR101801 (Phase Ib)
Phase Ib (dose expansion):25 and 100 mg capsules Doses administered will be determined from Phase Ia data.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Female or male patients aged ≥ 18 years.
3. ECOG performance status ≤ 2.
4. Life expectancy more than 3 months.
5. Phase Ia:Patients with relapsed and/or refractory relapsed/refractory B-cell lymphoma, CLL/SLL, and PTCL diagnosed with World Health Organization (WHO) classification
6. Phase Ib: Subjects with PTCL NOS, PTCL AITL, Nodal PTCL with TFH and PTCL FTCL.
7. Patients have measurable disease based on the appropriate tumor type criteria( Phase Ib only)
8. Have a current need for systemic therapy, the assessment of the investigator.
9. An archival or fresh tumor tissue (ie, tissue block or series of at least 5 slides, up to 15 slides) is required and should be provided during the Screening Visit for Lymphoma subjects. Local review of pathology is required for study entry in Phase Ib only.
10. Phase Ia subjects should be prepared to undergo a fresh tumor biopsy during the study (tumor biopsies will be obtained from 1 to 2 subjects per cohort in Phase Ia).
11. Subject having laboratory values defined as:
* Creatinine clearance (measured or calculated per institutional standard practice) ≥ 60 mL/min. GFR can also be used in place of creatinine clearance.
* Total bilirubin \< 1.5 × ULN, except for subjects with Gilbert's syndrome who are excluded if total bilirubin \> 3.0 × ULN or direct bilirubin \< 1.5 × ULN.
* ALT \< 2.5 × ULN, except for subjects who have tumor involvement of the liver, who are included if ALT \< 5 × ULN.
* AST \< 2.5 × ULN, except for subjects that have tumor involvement of the liver, who are included if AST \< 5 × ULN.
* Absolute neutrophil count \> 1.0 × 109/L.
* Platelet count \> 75 × 109/L.
* Hemoglobin \> 8 g/dL.
Exclusion Criteria
2. Impaired cardiac function or clinically significant cardiac disease
3. Patients with interstitial pneumonia or history of drug-induced interstitial pneumonia/pneumonitis.
4. Human immunodeficiency virus (HIV) infection.
5. Patients who are positive for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C virus antibody (HCVAb).
6. Chronic liver disease or chronic hepatitis
7. Any gastrointestinal disorders interfering with study drug absorption or are unable to swallow tablets or capsules.
8. Malignant disease, other than that being treated in this study.
9. Prior PI3K inhibitor will be accepted in the dose escalation part of the study (Phase Ia) only.
10. For patients with lymphoma:
* Systemic antineoplastic therapy (including cytotoxic chemotherapy, alfa-interferon \[INF\], and toxin immunoconjugates) or any experimental therapy within 3 weeks or 5 half lives, whichever is shorter, before the first dose of study treatment.
* Therapy with tyrosine kinase inhibitor within 5 half-lives before the first dose of study treatment.
* Unconjugated monoclonal antibody therapies \< 6 weeks before the first dose of study treatment.
11. Patients receiving systemic chronic steroid therapy or any immunosuppressive therapy (≥ 10 mg/day prednisone or equivalent).
12. Use of any live vaccines against infectious diseases within 4 weeks of initiation of study treatment.
13. Use of hematopoietic colony-stimulating growth factors, thrombopoietin mimetics, or erythroid-stimulating agents ≤ 2 weeks prior to start of study drug.
14. Patients with a history of stroke or having active neurological symptoms, with the exception of chronic conditions which, in the opinion of the neurologist, Investigator, and the Sponsor, would not impact ongoing neurologic assessments while on study treatment.
15. Active infection requiring systemic or antiviral antibiotic therapy.
16. Subjects with active CMV infection.
17. Subjects receiving moderate or potent CYP3A4 inhibitors or inducers and are unable to withdraw until 2 weeks or 5 times longer than the half-life, whichever is shorter, before the first dose of study treatment.
18. Major surgery within 2 weeks of the first dose of study treatment (mediastinoscopy, insertion of a central venous access device, and insertion of a feeding tube are not considered major surgery).
19. Radiotherapy within 2 weeks of the first dose of study treatment, except for palliative radiotherapy to a limited-field, such as for the treatment of bone pain or a focally painful tumor mass.
20. Presence of CTCAE ≥ Grade 2 toxicity (except alopecia, peripheral neuropathy, and ototoxicity, which are excluded if ≥ CTCAE Grade 3) due to prior cancer therapy.
21. Participation in an interventional, investigational study within 2 weeks or 5 half-lives, whichever is shorter, of the first dose of study treatment.
22. Any medical condition that would, in the Investigator's judgment, prevent the subject's participation in the clinical study due to safety concerns, compliance with clinical study procedures, or interpretation of study results.
23. Pregnant or lactating women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin laboratory test.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boryung Pharmaceutical Co., Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
TM Kim, M.D, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Hospital
SJ Kim, M.D, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Samsung Medical Center
DH Yoon, M.D, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Asan Medical Center
Jorge Chaves, M.D, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Northwest Medical Specialities, PLLC
Emily Curran, M.D, Ph.D
Role: PRINCIPAL_INVESTIGATOR
University of Cincinnati
JS Kim, M.D, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Severance Hospital, Yonsei University Health System
EY Lee, M.D, M.S
Role: PRINCIPAL_INVESTIGATOR
National Cancer Center
JO Lee, M.D, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Bundang Hospital
DH Yang, M.D, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Chonnam National University Hospital
WS Lee, M.D, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Inje University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Henry Ford Hospital
Detroit, Michigan, United States
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Chonnam National University Hwasun Hospital
Hwasun, Jeollanam-do, South Korea
Inje University Busan Paik Hospital
Busan, , South Korea
Asan Medical Center
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
Seoul national university hospital
Seoul, , South Korea
Severance Hospital, Yonsei University Health System
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BR-101801-CT-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.